Bevacizumab + Folfox4 or Xelox2 as first- line treatment in colorectal cancer. Randomized phase II study.
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2528540
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: To estimate the effectiveness of the combination of Oxaliplatino and Capecitabine (XELOX-2) + bevacizumab measured in terms of objective response rate in non treaty advanced colorectal cancer treatment.
创建时间：
2011-07-15
